Is Rulemaking Old Medicine at the FDA?

DSpace/Manakin Repository

Is Rulemaking Old Medicine at the FDA?

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Carey, John C. en_US
dc.date.accessioned 2012-06-07T20:30:54Z
dc.date.issued 1997 en_US
dc.identifier.citation Is Rulemaking Old Medicine at the FDA? (1997 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852158
dc.description.abstract The first three parts of this paper describe the major burdens placed on agency rulemaking by each branch of the government over the past thirty years, with specific focus on the burdens that presently affect FDA rulemaking. Part V then analyzes the effect those burdens have had on FDA rulemaking. The analysis will demonstrate that the additional rulemaking requirements likely act to deter rulemaking at the agency. In conclusion, Part VI briefly discusses the type of policymaking in which FDA currently engages as an alternative to rulemaking and describes further research to be done regarding that method of FDA policymaking. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject rules en
dc.subject rulemaking procedures en
dc.subject rulemaking processes en
dc.title Is Rulemaking Old Medicine at the FDA? en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-06-07T20:30:54Z

Files in this item

Files Size Format View
jcarey.pdf 375.4Kb PDF View/Open
jcarey.rtf 147.9Kb RTF file View/Open
jcarey.html 157.2Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters